DURHAM, N.C. , Sept. 03, 2024 (GLOBE NEWSWIRE) -- Humacyte , Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, today announced that Laura Niklason , M.D., Ph.D., Founder, President, and Chief...
- Results presented at the Department of Defense’s Military Health System Research Symposium (MHSRS) - - In real-world military setting the ATEV was observed to have 12-month patency of 87.1% - - There were zero instances of infection, amputation or death during the long-term follow-up period...
-FDA requires additional time to complete its review of ATEV™ (acellular tissue engineered vessel) BLA for the Treatment of Vascular Trauma- -Reported Positive Topline Results from Phase 3 Trial of ATEV in Hemodialysis Access- -ATEV Received Third Regenerative Medicine Advanced Therapy (RMAT)...
DURHAM, N.C. , Aug. 12, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, will release its financial results for the second quarter ended June 30, 2024 , on...
– 2 nd quarter conference call to be held Tuesday, August 13 th , at 8:30 a.m. ET – DURHAM, N.C. , Aug. 09, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale,...
– ATEV demonstrated superiority at six and 12 months (co-primary endpoints) compared to autogenous fistula, the current standard of care for hemodialysis – – Detailed results to be presented at upcoming medical conferences – DURHAM, N.C. , July 31, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc....
DURHAM, N.C. , July 16, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, announced the addition of pharmaceutical industry veteran Dr. John P....
– Third RMAT designation by FDA for ATEV – – RMAT will expedite development of ATEV in PAD – DURHAM, N.C. , July 01, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial...
– BioVascular Pancreas (BVP) product candidate is under development as a potential treatment for type 1 diabetes – – Humacyte’s stem cell-derived islets observed to restore normal blood glucose in diabetic mice – – Non-human primate models of BVP implantation showed islet survival and continued...
– Four unique ICD-10-PCS codes, effective October 1, 2024 , for replacement of arteries in the upper and lower extremities using Humacyte’s HAV – – BLA submission under Priority Review by FDA for the treatment of vascular trauma, supported by Phase 2/3 clinical trial results and real-world use...
